Products
FBXO9 antibody
- Product Name
- FBXO9 antibody
- Catalogue No.
- FNab03051
- Size
- 100μg
- Form
- liquid
- Purification
- Immunogen affinity purified
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- polyclonal
- Isotype
- IgG
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- F-box protein 9
- Alternative Names
- FBX9 antibody, VCIA1 antibody
- UniProt ID
- Q9UK97
- Observed MW
- 52 kDa
Application
- Tested Applications
- ELISA, WB, IHC
- Recommended dilution
- WB: 1:500-1:2000; IHC: 1:20-1:200
Validated Images
human liver tissue were subjected to SDS PAGE followed by western blot with FNab03051(FBXO9 antibody) at dilution of 1:300
Immunohistochemistry of paraffin-embedded human prostate cancer using FNab03051(FBXO9 antibody) at dilution of 1:50
- Background
- Substrate recognition component of a SCF(SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of TTI1 and TELO2 in a CK2-dependent manner, thereby directly regulating mTOR signaling. SCF(FBXO9) recognizes and binds mTORC1-bound TTI1 and TELO2 when they are phosphorylated by CK2 following growth factor deprivation, leading to their degradation. In contrast, the SCF(FBXO9) does not mediate ubiquitination of TTI1 and TELO2 when they are part of the mTORC2 complex. As a consequence, mTORC1 is inactivated to restrain cell growth and protein translation, while mTORC2 is activated due to the relief of feedback inhibition by mTORC1.
